Delage, J. A.
Faivre-Chauvet, A.
Fierle, J. K.
Gnesin, S.
Schaefer, N.
Coukos, G.
Dunn, S. M.
Viertl, D.
Prior, J. O. http://orcid.org/0000-0003-1429-1374
Funding for this research was provided by:
Alfred and Annemarie von Sick Grant
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland
Article History
Received: 11 May 2020
Accepted: 6 August 2020
First Online: 17 August 2020
Ethics approval and consent to participate
: All applicable institutional and/or national guidelines for the care and use of animals were followed. In particular, all animal experiments in the present study were conducted according to the Swiss federal law on animal experimentation under the cantonal authorization number VD-2993.
: Not applicable.
: George Coukos has received grants, research support, or is coinvestigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance, and Kite. Prof. Coukos has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure, and GeneosTx. Prof. Coukos has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. George Coukos holds patents around TEM1 antibodies and receives royalties from the University of Pennsylvania regarding technology licensed to Novartis.Julie K. Fierle and Steven M. Dunn hold patents in the domain of antibodies and in particular on the 1C1m antibody used in this study.All other authors declare that they have no conflict of interest.